Figure 2

Kaplan-Meier survival analysis of HIV disease progression to CD4 count < 350 cells/uL among. (A) 73 CSW cohort participants who seroconverted during follow-up: 21 GNB3 825CC/CT subjects and 52 GNB3 825TT subjects. There were no significant differences in time to CD4 < 350 as determined by Cox proportional hazard analysis [HR 0.665, 95% CI 0.369, 1.198, p = 0.1742]. (B) 146 HIV-1-positive CSW cohort subjects: 48 GNB3 825CC/CT subjects and 98 GNB3 825TT subjects. Following adjustment for baseline CD4 count, there were no significant differences in time to CD4 < 350 as determined by Cox proportional hazard analysis [HR = 0.956, 95% CI 0.619, 1.477, p = 0.8397]. (C) 262 PHT cohort HIV-1-positive mothers: 125 GNB3 825CC/CT subjects and 137 GNB3 825TT subjects. Following adjustment for baseline CD4 count, there were no significant differences in time to CD4 < 350 as determined by Cox proportional hazard analysis [HR = 0.75, 95% CI 0.47, 1.19, p = 0.22].